Swiss Re AG · SIX:SREN

Swiss Re — Swiss Re Expert Forum on Genomic Medicine 2018

33 slides from Swiss Re's conference presentation, Oct 23, 2018

  1. Slide 1: Genetics and Genomics: A view from daily practice in oncology

    Swiss Re: Genomic Medicine 2018 Genetics and Genomics A view from daily practice in oncology today and tomorrow Swiss Re Expert Forum on Genomic Medicine 22 / 23 October 2018 Rüschlikon/Zürich

  2. Slide 2: Conflict of Interests

    Swiss Re: Genomic Medicine 2018 2 Conflict of Interests ∙ My institution / myself receive honoraria and contributions from: ∙ Amgen, AstraZeneca, Eli Lilly, Genomic Health, Pfizer, Swiss Government (SIPH) ∙ I own stock of Novartis and Roche ∙ The Swiss Group for Clinical Cancer Research SAKK receive

  3. Slide 3: Oncology and Genomics: Tests are done on all Levels

    Swiss Re: Genomic Medicine 2018 4 Oncology and Genomics Tests are done on all Levels - daily ∙ Body Which gene-test? Which diagnosis ? ∙ Organ ∙ Tissue ∙ Cell 24.10.2018 Referent / Bereich

  4. Slide 4: Oncology and Genomics: Tests are done on all Levels

    Swiss Re: Genomic Medicine 2018 5 Oncology and Genomics Tests are done on all Levels - daily ∙ Protein ∙ Chromosomes ∙ RNA ∙ DNA FISH Mutations and more... 24.10.2018 Referent / Bereich

  5. Slide 5: Hereditary Breast und Ovarian Cancer-Syndrom HBOC

    Swiss Re: Genomic Medicine 2018 Hereditary Breast und Ovarian Cancer-Syndrom HBOC • +100% BRCA mutation analyses • Increase in prophylactic mastectomies and plastic surgery Angelina Jolie Effect > prolonged global increase in genetic counseling 6

  6. Slide 6: The Wave

    Swiss Re: Genomic Medicine 2018 7 The Wave 24.10.2018 Referent / Bereich

  7. Slide 7: Genetic Counceling Breast Center KSSG

    Swiss Re: Genomic Medicine 2018 |8 Genetic Counceling Breast Center KSSG 1 MedOnc 0.1 Med Geneticist 5 MedOnc 2 Surgeon 0.1 Med Geneticist 25.09.2018 | GL / Genetik Salome Riniker / Brustzentrum

  8. Slide 8: Molecular Genetic Analysis

    Swiss Re: Genomic Medicine 2018 |9 Molecular Genetic Analysis ∙ NGS-Method (Next Generation Sequencing) faster, cheaper, more genes (Panel)  Germline testing genetic analysis on healthy tissue Speziallabs for Medical Genetics GUMG, genetic counceling mandatory, request for cost coverage  Somatic t

  9. Slide 9: How is allowed to order germline genetic testing?

    Swiss Re: Genomic Medicine 2018 | 10 How is allowed to order germline genetic testing ? 25.09.2018 | GL / Genetik Salome Riniker / Brustzentrum

  10. Slide 10: Regulations and Access

    Swiss Re: Genomic Medicine 2018 | 11 Regulations and Access • are a problem because - lacking behind the technology - clinical + cost-benefit evidence cannot be or is not generated fast enough • only 4 cancer syndromes have a reimbursement regulation through KLV - HBOC, HNPCC, polyposis coli, retino

  11. Slide 11: Genetic HBOC Testing and

    Swiss Re: Genomic Medicine 2018 14 Genetic HBOC Testing and ∙ > increase in surveillance ∙ > massive increase in prophylactic surgery both in patients and heathy women ∙ > massive increase in plastic surgery: DIEP 24.10.2018 Referent / Bereich

  12. Slide 12: Genetic HBOC Testing and

    Swiss Re: Genomic Medicine 2018 15 Genetic HBOC Testing and ∙ 2 operation teams, 4 surgeons 8-9 h ∙ and specialised nursing for surveillance on specialised ward ∙ and.... 24.10.2018 Referent / Bereich

  13. Slide 13: Genetic HBOC Testing and

    Swiss Re: Genomic Medicine 2018 17 Genetic HBOC Testing and ∙ and 6 -12 months ∙ and some minor surgeries later 24.10.2018 Referent / Bereich

  14. Slide 14: Genetic Testing on Tumor Tissue/Cells

    Swiss Re: Genomic Medicine 2018 18 Genetic Testing on Tumor Tissue/Cells ∙ is routine on all biological levels ∙ varies widely across tumor types and drugs available ∙ Examples of medical management today ∙ Testicular Cancer ∙ Lung Cancer ∙ Breast Cancer 24.10.2018 Referent / Bereich

  15. Slide 15: Testicular Cancer

    Swiss Re: Genomic Medicine 2018 19 Testicular Cancer ∙ No testing is done ∙ No molecular target is availbe ∙ No targeted drug is availble ∙ Patients receive surgery and chemotherapy ∙ Almost all patients are cured with surgery and chemotherapy, even in advanced stage 24.10.2018 Referent / Bereich

  16. Slide 16: Genetic Testing on Tumor Tissue/Cells: Lung Cancer today

    Swiss Re: Genomic Medicine 2018 20 Genetic Testing on Tumor Tissue/Cells ∙ is routine on all biological levels ∙ varies widely across tumor types and drugs available ∙ Example: Lung Cancer today 24.10.2018 Referent / Bereich

  17. Slide 17: Lung Cancer

    Swiss Re: Genomic Medicine 2018 21 Lung Cancer ∙ Sub-type of lung cancer ∙ NSCLC ∙ Adeno, squamous, other, mixed ∙ Mutation panel Treatment with Alk-Inhibitors: Crizotinib Ceritinib More than 1 mutation ? How do they work together? Do you want to be an oncologist? 24.10.2018 Referent / Bereich

  18. Slide 18: Treatment with ALK Inhibitors

    Swiss Re: Genomic Medicine 2018 22 Treatment with ALK Inhibitors sustained chemo response < 10% ALK-Inhibitor response rate > 60% time to progression 13,4, months Relative rapid resistence Costs: CHF 69’000 /y CHF 74’000 /y 24.10.2018 Referent / Bereich

  19. Slide 19: Genetic Testing on Tumor Tissue/Cells: Breast Cancer

    Swiss Re: Genomic Medicine 2018 23 Genetic Testing on Tumor Tissue/Cells ∙ is routine on all biological levels ∙ varies widely across tumor types and drugs available ∙ Example Breast Cancer 24.10.2018 Referent / Bereich

  20. Slide 20: Breast Cancer: Prognostic and Predictive Markers

    Swiss Re: Genomic Medicine 2018 24 Breast Cancer: Prognostic and Predictive Markers ∙ Patient A.V. , born 17.01.81 ∙ Diagnosis: Invasive breast cancer left NST pT1c, pN2a (8/10), G2, BRE Score 6 (3,2,1) L1 focal, V0, ED 12/12 ER 90% IRS 12/12, PgR 100%, IRS 12/12 HER2 Dako-ICH: Score 2+, FISH Pathvi

  21. Slide 21: Breast Cancer: Primary Considerations

    Swiss Re: Genomic Medicine 2018 25 Breast Cancer: 3 Primary Considerations ∙ Magnitude of risk of recurrence after surgery ? Does the patient need further therapy to prevent spread of the tumor? Prognostic info ∙ If yes, how much can she benefit (relative and absolute) from which treatment? Predicti

  22. Slide 22: Breast Cancer: Prognostic and Predictive Markers IHC

    Swiss Re: Genomic Medicine 2018 26 Breast Cancer: Prognostic and Predictive Markers IHC 24.10.2018 Referent / Bereich

  23. Slide 23: Breast Cancer: Prognostic and Predictive Markers RNA

    Swiss Re: Genomic Medicine 2018 27 Breast Cancer: Prognostic and Predictive Markers RNA 21-gene-signature FISH 24.10.2018 Referent / Bereich

  24. Slide 24: Breast Cancer: Prognostic and Predictive Markers

    Swiss Re: Genomic Medicine 2018 28 Breast Cancer: Prognostic and Predictive Markers ∙ Patient A.V. , born 17.01.81 ∙ Diagnosis: Invasive breast cancer left NST pT1c, pN2a (8/10), G2, BRE Score 6 (3,2,1) L1 focal, V0, ED 12/12 ER 90% IRS 12/12, PgR 100%, IRS 12/12 HER2 Dako-ICH: Score 2+, FISH Pathvi

  25. Slide 25: Breast Cancer: Prognostic and Predictive Markers

    Swiss Re: Genomic Medicine 2018 29 Breast Cancer: Prognostic and Predictive Markers red: prognostic only green – blue – orange: prognistic and predictive ∙ Patient A.V. , born 17.01.81 ∙ Diagnosis: Invasive breast cancer left NST pT1c, pN2a (8/10), G2, BRE Score 6 (3,2,1) L1 focal, V0, ED 12/12 ER 9

  26. Slide 26: From Tumor-Biology to Treatment of the Patient: Step 1

    Swiss Re: Genomic Medicine 2018 30 From Tumor-Biology to Treatment of the Patient Breast Cancer Step 1 ∙ Standard information from pathology ∙ Assess recurrence risk ∙ Assess predictive chance and magnitude of risk reduction by ∙ Anti-hormonal treatment ∙ Chemotherapy ∙ Anti-HER2 therapy ∙ Other ava

  27. Slide 27: From Tumor-Biology to Treatment of the Patient: Steps 2-6

    Swiss Re: Genomic Medicine 2018 31 From Tumor-Biology to Treatment of the Patient Breast Cancer Steps 2 - 6 ∙ Assess biology and pharmacologic options ∙ Assess host (age, organs function, co-morbidities, medication, socio-cultural back-ground) ∙ Make recommendation(s) and give alternatives ∙ Ask for

  28. Slide 28: When you have no Standard Therapy (any more)

    Swiss Re: Genomic Medicine 2018 32 When you have no Standard Therapy (any more) ∙ Tumor gene profilig ∙ Fishing for «drug-able targets» ∙ mutations, overexpression, gene-amplification or deletions, silenceing ... . Gene-interactions? Driver and passengers? Is only a screenshot ! ∙ In most cases not

  29. Slide 29: Summary: Technology is the Driver

    Swiss Re: Genomic Medicine 2018 33 Summary: Technology is the Driver Access and Complexity are the Obstacles ∙ Genetic germline aberations ∙ The wave and it’s consequences for individuals and society ∙ Still, most cases of familiarity are unexplained ∙ If it comes to treatment, biology is the most i

  30. Slide 30: The future: Opportunities and Limitations

    Swiss Re: Genomic Medicine 2018 34 The future: Opportunities and Limitations Opportunities Limitations ∙ Starts now ∙ Faster than we can deal ∙ Better personalised prognosis ∙ Better personalised prognosis ∙ Better personalised prediction ∙ Better personalised prediction ∙ Liquid biopsy ∙ Overdiagno

  31. Slide 31: The End

    Swiss Re: Genomic Medicine 2018 35 Genetics and Genomics in Precision Medicine 2018 Glass has Glass is full half full The End half empty double size it should have half water half air 24.10.2018 Referent / Bereich

  32. Slide 32: Swiss Re: Genomic Medicine 2018

    Swiss Re: Genomic Medicine 2018 36 24.10.2018 Referent / Bereich

  33. Slide 33: Basic Copyright Notice & Disclaimer

    Basic Copyright Notice & Disclaimer ©2018 This presentation is copyright protected. All rights reserved. You may download or print out a hard copy for your private or internal use. You are not permitted to create any modifications or derivatives of this presentation without the prior written permiss

Swiss Re — Swiss Re Expert Forum on Genomic Medicine 2018 on 6ix